Fig. 4.

Kaplan-Meier survival estimator. For any subset of peptides, we bi-partioned peptides based on coexpression in samples. Next, we scored each sample based on the homogeneity of peptides from a single partition in that sample (Methods). The highest and lowest scoring samples (45% each) were grouped, and were tested to determine the clinical outcome. The Kaplan-Meier survival estimator and log-rank test were applied to test the difference of the clinical outcome of two groups. When testing with cooccurring mutated peptide/antibody peptide pairs, we observed a significant correlation with survival (Plot (A): p value = 0.032). In contrast, the correlation was reduced when testing with only antibody peptides (Plot (B): p value = 0.040), and there was no-correlation when testing with mutated peptides. (Plot (C): p value = 0.522).